DA
RAPT

Denali Advisors’s RAPT Therapeutics RAPT Stock Holding History

Denali Advisors’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,075
Closed -$293K – 395
2024
Q1 		$293K Buy
+4,075
New +$567K 0.09% 192

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Denali Advisors's RAPT Position: Q2 2024 in Review

Denali Advisors sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 4,075 shares — an estimated $293K sold.

Denali Advisors first reported a position in RAPT in Q1 2024 and held it in 1 quarter. The position peaked at $293K in Q1 2024. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • Denali Advisors reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Denali Advisors sold 4,075 RAPT Therapeutics shares in Q2 2024, an estimated $293K.
  • Denali Advisors first reported a position in RAPT Therapeutics in Q1 2024 and held it in 1 quarter.
  • Denali Advisors's RAPT Therapeutics position peaked at $293K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.